{"id":"W4378800385","doi":"10.1016/s1470-2045(23)00158-4","title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; BC Cancer Agency","funders":"National Cancer Institute; Medical Research Council; Advanced Accelerator Applications; Astellas Pharma; Clovis Oncology; AstraZeneca; National Institute for Health and Care Research; Novartis; Pfizer","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Radioligand; Quality of life (healthcare); Oncology; Internal medicine; Lutetium; Cancer; Nursing; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001761575,0.001779352,0.003329331,0.0004713981,0.000405292,0.00123945,0.001127278,0.002032393,0.005097707],"category_scores_gemma":[0.001704173,0.0006623022,0.003199141,0.0005925823,0.001640509,0.001171848,0.0005680672,0.003803433,0.0007452804],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001474549,"about_ca_system_score_gemma":0.001132752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002010402,"about_ca_topic_score_gemma":0.002901284,"domain_scores_codex":[0.9990048,0.0005505919,0.00004860177,0.0001598035,0.00007392631,0.0001623424],"domain_scores_gemma":[0.9990873,0.0002753879,0.0002517602,0.00006506146,0.0000517434,0.0002687944],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9836164,0.003175191,0.0005111989,0.0004451373,0.001197064,0.000014847,0.00003806832,0.0003957752,0.001313066,0.00008270384,0.0003614133,0.008849165],"study_design_scores_gemma":[0.918476,0.07771826,0.002030405,0.00002845273,0.0007143564,0.00002171987,0.00002134807,0.0003873243,0.0002549269,0.0001256132,0.0002028415,0.00001876642],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931266,0.003483571,0.0002794599,0.0004002832,0.0002524358,0.0009413952,0.0004488001,0.00006048023,0.001006981],"genre_scores_gemma":[0.9946225,0.001177594,0.0007138468,0.0004549346,0.0002552189,0.001125308,0.0005844234,0.00001485882,0.001051245],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005097707,"threshold_uncertainty_score":0.01705354,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09987168394441787,"score_gpt":0.4555469674960141,"score_spread":0.3556752835515963,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}